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SUMMARY 
 
Background 
 
In recent years, many workers exposed to manganese fumes have developed symptoms evoking 
occupational manganism. CSST (la Commission de la santé et de la sécurité du travail), the compensation 
body in the province of Québec was confronted with the fact that there were no standardized procedures 
for the primary, secondary and tertiary prevention of manganism, leading to possible medico-legal 
disputes and a possible lack of equity for workers or employers. 
 
Objective 
 
To establish the definition and classification of occupational manganism, provide medical specialists, and 
the compensation body with standardized procedures for the diagnosis, investigation, treatment and, 
monitoring of workers exposed to manganese (Mn), and with safe conditions for rehabilitation. 
 
Methods 
 
A medical committee was formed to provide answers on the clinical aspects of the problem; a synthesis of 
scientific knowledge was collected and a multidisciplinary panel of international experts was convened to 
reach, as much as possible, a consensual approach to the issue of diagnosis of manganism.  
 
Results 
 
Manganism is defined as a specific clinical central nervous system syndrome caused by manganese. 
Factors that might lead to manganism include excessive exposure, reduced clearance, increased absorption 
rate, and individual susceptibility to manganese. Then, occupational manganism could be defined as a 
specific clinical central nervous system syndrome caused by workplace exposure to manganese. Three risk 
factors were identified that have been shown to increase the accumulation of Mn in the central nervous 
system (CNS): liver diseases, iron deficiency and alcoholism, whose effects add to the neurotoxic action 
of Mn.  
 
Based on the level of diagnostic certainty, manganism can be classified as clinically possible, clinically 
probable or clinically definite. Independent of the level of diagnostic certainty, and based on the clinical 
assessment of functional and social capacities, impairment can be rated as mild, moderate or severe. 
 
Criteria have been proposed for classifying cases of occupational manganism. A worker is recognized as a 
clinically possible case of occupational manganism if the following three conditions are present: a 
documented identifiable source of occupational Mn exposure; at least one neurological element among 
tremor, bradykinesia, rigidity and postural instability and symptoms and clinical signs of 
neuropsychological disturbances, mainly motor ones. A diagnosis of a clinically probable case of 
manganism includes items from a possible case of manganism plus neuropsychological disturbances 
related to basal ganglia origin, absence or unsustained pharmacological response to levodopa (L-dopa) and 
exclusion of other neuropsychological diseases related to basal ganglia, such as Parkinson’s disease, 
secondary parkinsonism or atypical parkinsonism syndromes. Finally, a case of occupational manganism 
can be recognized as clinically definite if a clinically probable case is reinforced by histopathological 
data. A normal Fluoro-Dopa positron emission tomography (F-Dopa PET) scan is another approach that 
would also confirm clinically definite manganism, but an abnormal F-Dopa PET scan would not exclude 
manganism. 
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In order to diagnose a case of occupational manganism, a three-step approach is proposed. In the first step, 
for a worker suspected of having occupational manganism, the occupational physician should perform a 
thorough evaluation of Mn occupational exposure along with an evaluation of the presenting clinical 
picture. A clinical case history should also be performed that includes the history of current clinical 
symptomatology, the history of past clinical problems and the family history. He then performs a complete 
physical examination with an emphasis on neurological examination to identify clinical signs of 
parkinsonism. The physician should detail occupational exposure to any neurotoxic contaminants. Starting 
with an occupational history, he will search work records indicating Mn exposure and specific work 
assignments known to be associated with Mn exposure. He will also gather data, past or present, from 
occupational hygiene investigations (whenever these exist). If the occupational physician deems it 
appropriate, he could gather basic neuropsychological data using a standardized questionnaire and/or a 
short battery of tests and complementary investigations such as liver testing and complete blood count, 
and iron stores. Depending on the temporal relationship between the time of the Mn exposure and the 
examination, blood and urine Mn levels and a magnetic resonance imaging (MRI) could be ordered as 
well as other pertinent tests depending on the clinical history. After this initial data collection, he could 
refer the worker to a neurologist specialized in movement disorders if further exploration is deemed to be 
appropriate. 
 
In a second step, a neurologist knowledgeable in movement disorders should assess the patient to 
determine if the clinical picture is consistent with a diagnosis of manganism. Tests and procedures 
required to determine the correct diagnosis should be ordered as appropriate. 
 
In the third and final step, complementary investigations could include formal neuropsychological 
evaluation, MRI (if not already done and appropriate time-wise), levodopa trial and Fluorodopa PET scan 
or other imaging study to assess the integrity of the nigrostriatal system. Based on these assessments, the 
neurologist will determine if in his opinion a given case suffers from clinically possible, probable or 
definite manganism. The diagnosis may be modified based on subsequent examinations and the 
acquisition of further information. 
 
The experts agreed that there was no specific treatment plan for manganism. Antiparkinsonian drugs may 
have a positive effect on parkinsonian symptoms and signs, but this effect is temporary and of short 
duration, if present at all. Antioxidants have been recently studied but benefits have not been proven. 
Chelation is still considered investigational. Symptom relief and rehabilitation therapies are all that 
remain. The main intervention consists of stopping significant exposure to manganese as well as to other 
recognized neurotoxic agents as soon as possible, when the symptoms and signs may still be reversible. 
The experts also agreed on a medical monitoring plan in the first year and later as appropriate. If a change 
is seen in the worker’s condition, then the diagnosis can be reviewed. 
 
A worker considered as a definite, probable or possible case of occupational manganism and who has the 
physical capacity to work should be kept from any further significant exposure to manganese in the 
workplace. Furthermore, he should not be returned to a workplace significantly contaminated with any 
other recognized neurotoxic agent. The level of Mn exposure should be as low as possible but never 
exceed 0.03 mg Mn/m3 (expressed as respirable dust).  
 
A wide variety of psychoneurological tests have been used in studies of groups of asymptomatic 
individuals exposed to low doses of manganese. None of these functional tests is specific to the 
neuropsychological effects of manganese. However, a consistent pattern of abnormalities has been 
associated with manganese, including deterioration of the rapidity of neurosensorial response, motor 
function, mood, and memory tests.  There is no data from longitudinal studies allowing an assessment of 
the value of any test or combination of tests for predicting the occurrence of clinical manganism. On an 
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individual basis, it is thus impossible to predict who will develop a syndrome of clinical manganism 
among asymptomatic workers exposed to low doses of manganese and having some abnormal functional 
tests.  
 
Based on current scientific knowledge and the World Health Organization (WHO) criteria to be met in 
order to implement screening program and therefore good medical practice, no recommendation can be 
made for a screening program targeting asymptomatic workers exposed in the workplace. A prospective 
longitudinal controlled study could be useful to learn more about the progression from pre-manganism or 
some preclinical effects of Mn to clinical manganism.   
 
The only preventive intervention that could be proposed to reduce or eliminate the risk of developing 
clinical manganism is the reduction of exposure. 
 
Conclusion 
 
Valuable information on the clinical aspects of occupational manganism will lead to standardized 
procedures for the diagnosis and management of workers exposed to manganese fumes and dusts. CSST 
compensation parameters and management procedures for cases should be reconsidered taking into 
account the information included in the present report. 
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INTRODUCTION 
 
 
In recent years, many workers in the province of Québec have developed symptoms evoking manganism. 
Most of these people are welders exposed to manganese (Mn) fumes during heavy equipment 
maintenance. These workers have received medical, neurological, neuropsychological and psychiatric 
evaluations and some of them have been diagnosed as having manganism at different stages. Non-
standardized diagnostic procedures have been used and the conclusions could lead to medico-legal 
disputes. 
 
To deal efficiently with this emerging situation, a medical committee has been formed by the CSST; 
IRSST and physicians from the Québec prevention network were invited to participate. The IRSST and 
the CSST produced a synthesis of the scientific knowledge and different specialists have been consulted in 
the province of Québec. It has been concluded that establishing a diagnosis for manganism is particularly 
challenging since standardized evaluation protocols do not exist and important parameters to consider are 
controversial. 
 
A standardized evaluation procedure, on which all the representatives of the different stakeholders 
(workers, employers, the medical profession, the prevention network, IRSST and the CSST) could agree, 
seems strongly desirable for an optimal management of this particular situation. In fact, neurologists and 
other specialists should be able to come to the same conclusions when they meet a worker who has been 
exposed to manganese. The procedure should be known and shared among the specialists so that 
employers and workers as well as the CSST, which has to manage the compensation claims, know exactly 
the criteria leading to the conclusion of the claims.  
 
With the objective of proposing guidelines for the diagnosis of occupational manganism and the 
management of affected workers, the IRSST invited a group of five internationally renowned specialists to 
form an international panel that would guide the Québec medical committee on manganese. This panel 
included a neurologist (USA), a neuropsychologist (USA), an industrial physician (Italy), a toxicologist 
(Belgium) and a physician specialized in epidemiology and in community health (Québec). The first three 
are internationally renowned specialists on manganese, the fourth has extensive expertise in metal 
toxicology, and the fifth has worked on many international consensus panels and has acted as president of 
the panel. 
 
A mandate document and support document were prepared for the experts who then met twice for three 
days each time, at a two-month interval. The experts did work not only during, but also before, between 
and after the meetings. An extensive correspondence was exchanged with and between the experts to 
come to a consensus on each of the seven questions that were addressed by the medical committee 
members who also participated in the meetings but did not take a position in the establishment of the 
consensus. The stages of the study of the medical committee are summarized in Figure 1. 
 
This report, which has been peer-reviewed by other experts, give the final position of the five members of 
the experts’ panel, expressing the points on which the scientific knowledge lead to a consensus as well as 
the point on which a consensus was impossible to reach.  
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Figure 1. Stages of the study by the medical committee 
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MANDATE 1  
 
Propose a definition of manganism 
 
 
Recommendations 
 
Manganism is defined as a specific clinical central nervous system syndrome caused by manganese. 
 
This report focuses on central nervous system (CNS) aspects of manganese-related health effects. 
The manifestations of manganism may vary with duration and level of exposure. The clinical 
features include parkinsonism with neuropsychological and/or psychiatric disturbances. Manganism 
is related to the accumulation of manganese in the brain and may be related to occupational or other 
sources of exposure. It can be influenced by susceptibility risk factors, which act as effect modifiers. 
Factors that might lead to manganism could include: 
o Excessive exposure 
o Reduced clearance 
o Increased absorption rate 
o Individual susceptibility to manganese 
 
It should be noted that manganese can also affect other systems such as the respiratory and 
reproductive systems, but this is outside the scope of the present mandate. 
 
Occupational manganism could be defined as a specific clinical central nervous system syndrome 
caused by workplace exposure to manganese. 
 
 
Risk factors  
 
Some factors have been shown to increase the accumulation and effect of Mn on the CNS. Three 
risk factors were identified: 
o Liver diseases, which increase the body load of Mn; 
o Iron deficiency, which favours the entry of Mn in the CNS; 
o Alcoholism, whose effects add to the neurotoxic action of Mn.  
 
 
 
Consensus status 
 
These recommendations were agreed upon by consensus. 
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Rationale  
 
Occupational exposure to manganese 
 
Mn and some of its compounds are used in different industrial processes.  The most common forms 
are metallic Mn, Mn+2, Mn+3 and Mn+4 found mainly as MnCl2, MnSO4, MnPO4, MnO2 and Mn3O4. 
Alloyed with different metals, mainly iron, Mn makes these products extra hard.  Manganese 
chloride is used as a catalyst but also as an animal food supplement.  Manganese dioxide as well as 
chloride are both used in the manufacture of dry batteries.  Manganese dioxide also has several 
other applications: fireworks, matches and porcelain. Manganese sulfate is used as fertilizer, in 
ceramics, glazes and varnishes, as a food supplement, as well as a fungicide (ACGIH 2001). 
Manganese’s organic compounds have three main uses: manganese methyl cyclopentadienyl 
tricarbonyl (MMT) as an anti-knock additive in gasoline, two pesticides, (maneb and mancozeb), as 
well as mangafodipir used for diagnosing certain forms of hepatic cancers (ATSDR 2000; ACGIH 
2001). 
 
Occupational exposures to inorganic compounds of Mn occur almost solely from the inhalation of 
dusts and fumes containing Mn. They are mainly related to emissions from automobiles and trucks 
during maintenance in countries where MMT is used, as well as to the dusts from ores during 
extraction and processing, to steel preparation operations using Mn, in dry battery manufacturing 
plants, as well as in steel welding operations using manganese and electrodes with high Mn content 
(ATSDR 2000; ACGIH 2001; WHO 1986; HSDB 1993). 
 
Concentrations from 1.5 to 450 mg Mn/m3 have been reported in mines (US EPA 1984), 0.30 to 20 
mg Mn/m3 in ferroalloy production foundries (Saric et al. 1977), 3 to 18 mg Mn/m3 in the dry 
battery manufacturing sector (Emara et al. 1971), from 1 to 4 mg Mn/m3 in welding operations 
(Sjögren et al. 1990), and up to 14 mg Mn/m3 in welding operations with welding wire (CICADS 
1999). More recent studies, however, have reported much lower average concentrations of 1 mg 
Mn/m3 or less in several of these workplaces (Roels et al. 1985, 1987a, 1987b and 1992; Mergler et 
al. 1994; Lucchini et al. 1995).  For exposed workers, Mn absorption may become much more 
significant by inhalation than by ingestion through food (Ostiguy et al. 2003). 
 
Manganese absorption and distribution 
 
Manganese is an essential trace element that is thought to be primarily absorbed via the 
gastrointestinal tract and the lungs. Dietary manganese is largely excreted through the liver by way 
of biliary excretion and elimination in the feces. Manganese is a component of many proteins and 
can be found in almost every tissue in the body. It is an essential cofactor in several enzyme 
activities playing a role in bone mineralization, in protein and energy metabolism regulation, in 
cellular protection and in the formation of glycosaminoglycans (ATSDR 2000). However, long-term 
exposure to excessive levels can cause adverse health effects although there are many variables that 
are not completely understood such as particle size, formulation, solubility and bioaccumulation. 
The main target organ systems after chronic inhalation exposure to manganese are the lungs, and the 
reproductive and the central nervous systems.  
 
The level of absorption of manganese by the gastrointestinal tract is maintained between 3-5% in 
healthy individuals (Andersen et al. 1999; Mena et al. 1969; Davidsson et al. 1988; Oberdoerster 
1988; EPA 1995). 
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Absorption of manganese by inhalation is in relation to particle size, with the absorption level being 
close to 100% for small particles (diameter less than 1µm). Absorption by this route bypasses the 
control processes in the gastrointestinal tract. Manganese absorbed by inhalation is apparently 
oxidized to its trivalent form and binds to the iron-carrying protein, transferrin. Brain uptake of 
manganese occurs via transferrin receptors located in various brain regions (Andersen et al. 1999; 
Aschner et al. 1999). 
 
Several researchers suggest that the olfactory neurons could serve as an entry pathway for 
manganese to the brain. Intranasal infusion of manganese in animals resulted in manganese uptake 
directly into the olfactory bulb. Studies showed that manganese absorbed via primary olfactory 
neurons could migrate to other regions of the brain via secondary and tertiary olfactory neurons 
(Tjälve et al. 1996; Brenneman et al. 2000; Dorman et al. 2001, 2002). 
 
Absorption of manganese by the skin is negligible (ATSDR 2000). 
 
 
Manganism 
 
Chronic Mn exposure may lead to damage to the central nervous system, called manganism. 
Manganism is a progressive syndrome that typically begins with relatively mild, nonspecific 
symptoms, which can gradually evolve to a severely debilitating disease with some features that are 
similar to Parkinson’s disease (PD) (Mena et al. 1967; Rodier 1955; Inoue and Makita 1996; 
Olanow 2004; Schuler et al. 1957; Tanaka and Lieben 1969; Smyth et al. 1973; Yamada et al. 1986; 
Huang et al. 1989, 1993, 1998; Wennberg et al. 1991; Ky et al. 1992; Calne et al. 1994; Chu et al. 
1995; Hochberg et al. 1996; Mergler and Baldwin 1997; Pal et al. 1999). 
 
The exact biochemical mechanism responsible for manganese neurotoxicity is not clearly 
established (Aschner and Aschner 1991). Neuropathological changes are detectable in the basal 
ganglia of people with manganism. There is substantial evidence that the primary sites of damage 
are the globus pallidus, the striatum and the substantia nigra pars reticulata, while the nigrostriatal 
system is relatively spared (Olanow 2004; Yamada et al. 1986). 
 
Manganese toxicity shows great interindividual variability, and the exposure level for which no 
effect occurs is not well defined. The clinical effects of high-level inhalation exposure to manganese 
do not become apparent until several years, but some individuals may begin to show signs after as 
few as one to three months of exposure to very high concentrations (Rodier 1955). It appears that 
the occurrence of manganism cases increases with the duration of exposure, suggesting that the 
seriousness of the symptoms increases with cumulative exposure. (Roels 1987a, 1987b, 1992; 
Lucchini 1999; Rodier 1955; Schuler 1957; ATSDR 2000). 
 
It is hypothesized by many authors that the health effects, particularly on the central nervous 
system, occur in a “continuum of dysfunction” which would be dose-related (Mergler et al. 1999; 
ATSDR 2000; ACGIH 2001). In other words, slight and imperceptible effects may be caused by 
low but physiologically excessive quantities of Mn and these effects increase in severity when the 
exposure level and the duration increase. Manganese effects begin as a slow deterioration in well-
being, which can initially be detected as early neurofunctional changes detectable solely in exposed 
groups; later, as individual preclinical and then clinical signs; and finally, as a complete 
neurological disease whose development depends on the exposure dose, the exposure duration and 
individual susceptibility (Mergler et al. 1999). Overt manganism will then be a complex CNS 
syndrome involving damage to the regions of the brain most sensitive to Mn, and lead to a specific 
form of clinical parkinsonism. To our knowledge, no longitudinal epidemiological study exists that 
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has shown the progression from Mn overexposure to overt manganism. Because of the actually 
limited scientific knowledge on the progression of the disease and the challenges in establishing a 
diagnosis, Mandates 3 and 4 will discuss these aspects in detail. 
 
Many factors may increase the concentration of Mn in the CNS. 
 
Liver disease 
Since manganese is mainly excreted through the biliary pathway, individuals with chronic liver 
failure are at risk of developing hepatic encephalopathy, which would probably be caused by an 
accumulation of manganese in the brain (Butterworth et al. 1995; Krieger et al. 1995; Pomier-
Layrargues et al. 1995; Spahr et al. 1996; Layrargues et al. 1998).  It has been shown that 
portosystemic shunting, biliary atresia and liver dysfunction give rise to the accumulation of 
manganese in the brain (Hauser et al. 1996; Layrargues et al. 1998; Rose et al. 1999; Ikeda et al. 
2000). There is evidence that extrapyramidal signs related to manganese accumulation in the basal 
ganglia and minimal hepatic encephalopathy are linked in patients with cirrhosis (Jover et al. 2003). 
 
Iron deficiency 
Manganese and iron compete for the same carrier transport system. Plasma iron overload 
significantly decreases the uptake of manganese across the blood brain barrier, whereas iron 
deficiency (serum ferritin < 10-20 µg/L) is associated with an increased central nervous system 
burden of manganese (Mena et al. 1974; Aschner et al. 1990). 
 
There is clear evidence from animal studies that gastrointestinal absorption of manganese is 
inversely related to the iron concentrations in the diet. Hence, high concentrations of iron lead to a 
lower absorption of manganese, while low levels of iron promote manganese absorption (Baldwin et 
al. 1999; Chandra and Tandon 1973; Davis et al. 1992a, 1992b; Diez-Ewald et al. 1968; Rehnberg 
et al. 1982). 
 
Alcoholism 
Chronic alcoholic patients may develop liver disease that can lead to hepatic encephalopathy 
(Butterworth 2003). Also, anaemia is a common problem associated with alcoholism. Alcohol may 
induce a variety of effects on hematopoiesis, notably in damaging erythroid precursors and leading 
to anaemia in chronic alcoholics (Eichner 1973; Guthrie et al. 1983; Savage et al. 1986; Michot et 
al. 1987; Heermans 1998). Furthermore, there is some evidence of interaction between alcohol and 
manganese on mood states and an increase in neuropsychiatric symptoms (Sassine et al. 2002; 
Bouchard et al. 2003). 
 
Other factors 
Aging was not retained as a specific factor because of the lack of scientific evidence. However, it 
seems that it diminishes the ability of the brain to compensate and, in so doing, increases the 
susceptibility to neurotoxic effects (Pal et al. 2002; Mergler et al. 1999; Apostoli et al. 2000; Levy 
et al. 2005).  
 
Factors like gender and genetic factors may or may not increase the susceptibility of developing 
manganism. However, further studies are necessary in these fields of research.  
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MANDATE 2  
 
Propose a classification system for cases of manganism in relation to the 
severity of the disease and the level of diagnostic certainty 
 
Recommendations 
 
Level of diagnostic certainty 
Manganism can be classified as: 
 
o Clinically possible  
o Clinically probable 
o Clinically definite 
 
Criteria used to define this classification are discussed in the next chapter (Mandate 3). 
 
 
Severity scale 
 
Independent of the level of diagnostic certainty, and based on clinical assessment of functional 
and social capacities, impairment can be rated as: 
 
o Mild  
o Moderate 
o Severe 
 
Rating scales used to assess the severity and impact of Idiopathic Parkinson Disease (IPD) may be 
helpful. In Québec, the most widely used rating scale is the Unified Parkinson Disease Rating Scale 
(UPDRS). 
 
 
Consensus status 
 
These recommendations were agreed upon by consensus. 
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Rationale 
 
Level of diagnostic certainty 
 
Diagnosis of manganism is difficult. The experts on the panel all agreed that a simple scale 
reflecting levels of diagnostic confidence would be helpful. Criteria used to classify cases of 
manganism are based on different sources such as:  
 
o Exposure data 
o Clinical data  
o Pharmacological data  
o Neuro-imaging data  
o Pathological data.  
 
Using these different sources of data, one can classify cases of manganism according to the level of 
etiological certainty that a clinician can assert. They can be rated as: 
 
o Clinically possible  
o Clinically probable 
o Clinically definite 
 
The clinical criteria used for such classification are the subject of the next mandate and will not be 
discussed here. 
 
 
Severity scale 
 
Regarding the severity scale based on clinical assessment of functional and social capacities, the 
impairment can be rated as: 
 
o Mild 
o Moderate  
o Severe 
 
In fact, the endpoint is to recognize and quantify the reduction in the autonomy of the affected 
workers taking into account cognitive and emotive aspects.  
 
Rating scales used to assess the severity and impact of Parkinson’s disease (PD) already exist. 
Parkinson's disease is a progressive neurodegenerative disorder. Motor functions of patients with 
Parkinson's disease are determined by its cardinal symptoms: bradykinesia, tremor, rigidity and 
disturbed postural reflexes. To evaluate the degree of disability and the rate of progression, simple 
but reliable and reproducible rating scales are essential.  These or some of these could be used to 
correctly assess the autonomy of a given individual affected by manganism. Emphasis should be put 
on functional and social capacities. 
 
Some examples of widely used rating scales developed to assess Parkinson’s disease are listed 
below. These can be used as well to assess the autonomy of patients affected by manganese 
exposure in evaluating their functional and social capacities. 
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Activities of Daily Living (ADL) 
The ADL scale measures the impact of PD on 14 categories of routine daily life (Newton and Brody 
1969).  
 
Schwab and England Activities of Daily Living 
The Schwab and England scale reflects the patient’s ability to perform daily activities in terms of 
speed and independence (Schwab and England 1969). 
 
Hoehn and Yahr Staging of Parkinson’s Disease 
This was the simplest and most popular severity scale for PD (Hoehn and Yahr). However, it lacks 
sensitivity to changes in the patient’s functional condition. This system has been largely supplanted 
by the more complicated UPDRS. 
 
Unified Parkinson Disease Rating Scale (UPDRS) 
The UPDRS is a rating tool to follow the longitudinal course of Parkinson’s disease. It is an overall 
assessment scale that quantifies all the motor and behavioural aspects of the disease as a single 
number. It is widely used in clinical research and drug trials (Fahn and Elton 1987).  
 
The Movement Disorder Society Task Force on rating scales for Parkinson’s disease prepared a 
critique of the UPDRS. The strengths of the UPDRS are its wide utilization, its wide clinical 
spectrum of PD, its coverage of motor symptoms and its clinimetric1 properties, including reliability 
and validity. Its weaknesses: some ambiguities in the text, some metric flaws and the absence of 
screening questions on several important non-motor aspects of PD.  
 
The Movement Disorder Society Task Force recommended that the Movement Disorder Society 
sponsor the development of a new version of the UPDRS and encourage efforts to establish its 
clinimetric properties as well as test its correlation with the current UPDRS (Movement Disorder 
Society Task Force on Rating Scales for Parkinson’s Disease 2003). Indications are that it has been 
done and will shortly be published. 
                                                 
1  Clinimetric properties are to be defined as “overall quality of a scale in regard to its internal validity and external 
validity. Internal validity includes concepts as construct validity, content validity, and predictive validity 
(sensitivity, specificity, predictive positive value, etc…). External validity relates more to reliability considerations 
i.e. reproducibility” (Feinstein 1984; Nunnaly 1978).   
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Consensus status 
 
These recommendations were agreed upon by consensus  except  
for the use of  the F-Dopa PET scan to confirm a definite case.  
 
MANDATE 3  
 
Propose criteria for classifying cases of occupational manganism and for 
differentiating them from other neurological pathologies, including idiopathic 
Parkinson’s disease 
 
Recommendations 
 
Many tests exist that can contribute to the establishment of a diagnosis of manganism. However, many of 
these tests have important limitations and scientific knowledge on the development of the disease is rather 
limited. With this scientific gap, a standardized and recognized list of criteria leading to the diagnosis of 
manganism does not exist. Based on current knowledge, the following classification is proposed. 
1) A clinically POSSIBLE case of occupational manganism would include: 
a. A documented identifiable source of occupational Mn exposure 
b. At least one neurological element among tremor, bradykinesia, rigidity and postural 
instability 
c. Symptoms and clinical signs of neuropsychological disturbances, mainly motor 
Such a picture would warrant public health interventions in order to implement preventive 
measures.  
 
2) A clinically PROBABLE case of manganism would include: 
o Items from a possible case of manganism plus: 
o Neuropsychological disturbances related to basal ganglia origin 
o Absence or unsustained pharmacological response to L-dopa 
o Exclusion of other neuropsychological diseases related to basal ganglia, such as 
Parkinson’s disease, secondary parkinsonism or atypical parkinsonism syndromes.  
 
3) A clinically DEFINITE case of occupational manganism would include: 
o Items from a probable case plus: 
o Histopathological data 
OR  
o A normal F-Dopa PET scan would confirm manganism but an abnormal F-Dopa PET 
scan would not exclude manganism. 
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Rationale 
 
Manganism is one of the clinical syndromes in the broad category of neurodegenerative disorders 
presenting with parkinsonism. Since manganese neuro-intoxication is classically associated with Mn 
accumulation in, and damage to, the globus pallidus, striatum and substantia nigra pars reticulata, 
with relative sparing of the nigrostriatal dopaminergic system2 (Yamada et al. 1986; Calne et al. 
1994; Olanow et al. 1996; Sziraki et al. 1998; Newland 1999; Normandin and Hazell 2002; Olanow 
2004), its clinical presentation and pharmacological response to levodopa, as well as images 
stemming from different technologies and histopathological evidence, will reflect this particularity 
and help differentiate manganism from other types of parkinsonism (Calne et al. 1992; Pal et al. 
1999). However, the reader must keep in mind that a limited number of cases are described in the 
scientific literature, which remains insufficiently documented, and many questions are still 
unanswered. Among these is the progression of symptoms as the disease evolves from early non-
specific health effects to chronic manganism.  
- Early health effects of chronic Mn exposure  
Before the appearance of signs of overt manganism, workers exposed to low levels of Mn dusts and 
fumes can present non-specific subtle symptoms that are labelled in the literature as sub-clinical or 
pre-clinical. These subtle effects can constitute manganese-induced changes in the same areas of the 
brain as overt manganism, namely the basal ganglia and particularly the globus pallidus, striatum 
and substantia nigra pars reticulata. It is quite plausible, although it has not been proven, that these 
early effects could be of relevance to later clinical disease without being clearly predictive. It 
remains that the most sensitive end point of Mn toxicity is neurological/neuropsychological. In the 
last fifteen years, health research on Mn has been centred on the evaluation of these subclinical 
neurobehavioral / neurotoxicological early effects of chronic exposure to low-levels of Mn dusts 
and fumes. To our knowledge, no large scale epidemiologic study has been done that quantifies the 
risk of developing parkinsonism following the appearance of subtle early effects. 
These early effects are mainly motor but they can also be cognitive. They should concern mainly: 
o Deficit in attention allocation and filtering; 
o Impaired implicit learning and memory leading usually to acquisition of behaviours and 
efficiency in working memory by motor learning, sequencing and movements (Ring et al. 
2002). 
 
A careful neuropsychological examination using a standardized battery of tests should help identify 
these deficits early in the diagnostic process. A short and a thorough versions of batteries of tests are 
presented in Appendices A, B and C. It is important to take into account the fact that, most of the 
time, the very early symptoms and signs are nonspecific as described earlier and are usually 
dependent on the degree of exposure. 
  
 Five sets of data can be used to evaluate a suspected case of occupational manganism. These are: 
o Occupational exposure data 
o Clinical data 
o Pharmacological data 
o Imaging data 
o Histopathological data  
                                                 
2  It is to be remembered that classical idiopathic Parkinson’s disease (IPD) is characterized by degeneration of 
dopamine neurons in the substantia nigra compacta (Calne 1994; Olanow 2004). 
IRSST Management of Occupational Manganism: 
Consensus of an Experts’ Panel 
 
 
 
13
Each has its utility and will intervene at different points in time during proper evaluation of a 
suspected case, but overall, the gathered information will be mainly relevant in two ways: first to 
evaluate the nature and extent of disability in an afflicted individual and second to establish a causal 
relationship between the observed clinical picture and manganese exposure. Using bits of 
information given alternatively by each set, a clinician will gain confidence in his assertion that a 
given case is indeed a case of occupational manganism and not any other parkinsonian disorder. As 
the overall picture of the case evolves, the clinician will progressively be able to label a case as 
accurately as possible as, clinically possible, clinically probable, or clinically definite (Jankovic et 
al. 2000; Hobson 2003). Some of the information given by each set of data will serve to establish a 
case while some other information will serve to exclude other diseases as alternative explanations 
for the presenting clinical extra-pyramidal syndrome (Litvan et al. 2003). 
 
- Occupational exposure documentation 
Basically and of utmost importance, one should consider that a case could be occupational 
manganism if there is a source of documented occupational exposure to excessive levels of Mn.  
It is possible that some individuals with a reduced clearance for Mn, increased absorption or 
individual increased susceptibility, such as people with alcoholism, liver cirrhosis or iron reserve 
depletion, may develop a syndrome of manganism when exposed to levels of Mn that do not cause 
intoxication in healthy subjects (Devenyi et al. 1994; Hauser et al. 1994, 1996; Layrargues et al. 
1995; Pomier-Layrargues et al. 1995; Spahr et al. 1996; Herrero Hernandez et al. 2002; Ellingsen et 
al. 2003; Fiedler 1996). Toxic exposure could be a function of exposure duration and exposure 
intensity. It is possible that a cumulative index will more likely be associated with the development 
of symptomatic manganism (Chandra et al. 1981; Roels et al. 1987a and b, 1992; Lauwerys et al. 
1987; Iregren 1990, 1992,1996; Feldman 1992; Chia et al. 1993a and b; Mergler et al. 1994; 
Lucchini et al. 1995, 1997, 1999; Sjögren et al. 1996; Gibbs et al. 1999; ATSDR 2000; Ostiguy et 
al. 2003). It is important to note that symptoms and signs can persist or progress long after exposure 
to Mn has stopped (Huang et al. 1989; Pal et al. 1999; Roels et al. 1999). 
 
Historical as well as current exposure data coming from different sources will be used, such as3: 
o Work history records indicating Mn exposure or work assignments known to be associated with 
Mn exposure; reports, past or present, from occupational hygiene investigations (whenever 
these exist).   
o Biological measurements (Huang et al. 1989), such as blood or urine Mn, only reflect recent 
exposure and, on an individual basis, are poorly correlated to current Mn exposure (Chandra et 
al. 1981; Roels et al. 1987; Jarvisalo et al. 1992; Bader et al. 1999; Apostoli et al. 2000; 
Ellingsen et al. 2003). They also poorly reflect the body burden of Mn, although blood Mn can 
be associated with cumulative exposure a few days after cessation of exposure (Lucchini et al. 
1995). Adverse health effects due to previous higher exposure can be present in the absence of 
positive biological measurements when the patient is diagnosed (Roels et al. 1987; Huang et al. 
1998). Biological measurements are not correlated to the ulterior development of clinical 
manganism (Jimenez-Jimenez et al. 1995). 
o The CaNa2EDTA (ethylenediaminetetraacetic acid calcium and sodium salts) mobilization test 
could be used to document a high body burden of Mn (Feldman 1992; Discalzi et al. 2000); 
                                                 
3  Evidence from one of these is usually sufficient to establish excessive exposure. 
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however, since reference values are not established, it is still considered an experimental 
procedure. 
o MRI may also provide a measure of manganese exposure within no more than 4-6 months of 
exposure to Mn, with a high signal in the globus pallidus and striatum on the T1-weighted 
image. Note that MRI signal can be seen in patients who are clinically intact. This aspect will 
be discussed in detail on page 15. 
 
Biomarkers of exposure should be assessed in a timeframe that reflects the half-life of Mn in the 
body: negative results when these tests are performed more than 4 to 6 months after cessation of 
exposure are not conclusive of non-exposure. The half-life of Mn is about 10-42 days in blood and 
more than 200 days in the brain (Mena et al. 1967; Newland et al. 1987). 
 - Clinical data 
To illustrate the historical difficulty inherent in making the right diagnosis, it has been shown that, 
within a typical movement disorder clinic, only about 75 per cent of patients with a parkinsonian 
syndrome and who were diagnosed as having PD turn out to have pathological changes of PD at 
post mortem (Duffau et al. 2002). Other forms of parkinsonism that could be mistaken for PD 
include Multi-System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP). The latter two 
syndromes are more similar, clinically, to manganism than is Parkinson's disease: the pathologies of 
PSP and MSA manifest in the basal ganglia, and are only minimally responsive to L-dopa. Very 
little is known about the etiology of PSA and MSA. An analysis indicated that the features that most 
accurately predict PD pathology with damage to the substantia nigra pars reticulata are: a) resting 
tremor, b) asymmetry of motor features, and c) poor or unsustained response to levodopa. Using 
these criteria, a correct diagnosis of PD with damage to the substantia nigra pars reticulata was 
established at post mortem in 98.6% of cases (Ward and Gibb 1990; Hughes et al. 1992, 2002). This 
illustrates that these features can help to differentiate Parkinson patients with PD from patients with 
parkinsonism due to other causes.  
 
From the comparison they have made between IPD and manganism, Calne et al. (1994) and Olanow 
(2004) drew the following conclusions:  
1. There are similarities between PD and manganism, notably the presence of (a) generalized 
bradykinesia and (b) widespread rigidity. 
2.  There are also dissimilarities between PD and manganism. In PD, patients are more likely to 
have parkinsonism with resting tremor, asymmetry, and a good response to levodopa. Patients 
with manganism are more likely to have: (a) less frequent and atypical tremor, (b) more frequent 
dystonia (especially grimacing and cock walk), (c) a particular propensity to fall backward early 
on, (d) failure to achieve a good or sustained therapeutic response to levodopa, and (e) absence 
of reduced striatal fluorodopa uptake as assessed by PET.  
At an early stage, psychiatric symptoms could dominate the clinical picture of manganism (Calne et 
al. 1994; Olanow, 2004) but the precise symptoms and clinical signs of neuropsychological 
disturbances remain to be documented (Dietz et al. 2001).  
 
These early disturbances reported for Mn overexposure are mainly motor, but other deficits related 
to basal ganglia alterations such as deficits in attention, memory and implicit learning can lead to 
reduced motor learning, coordination, and sequencing (Bowler et al. 1999; Bowler et al. 2003). 
Some functional neuropsychological tests, related more specifically to deterioration of the rapidity 
of neurosensorial response, motor function and memory, were reported to be more likely altered 
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early in Mn chronic exposure (Johnson et al. 2004). These tests are hand-eye coordination, hand 
steadiness and simple visual reaction time (Wennberg et al. 1991; Iregren 1992; Lucchini et al. 
1995, 1999; Mergler and Baldwin 1997; Iregren 1999; Roels et al. 1999). Nonetheless, the scope 
and extent of the neuropsychological alterations will extend as the severity of the CNS alteration 
increases. However, careful neuropsychological examination using a standardized battery of tests 
will help identify these alterations more precisely (Mergler et al. 1994; Despres et al. 2000). Such 
batteries of tests are listed in Appendices A, B and C. These alterations, although very sensitive and 
usually dependent on the degree of exposure, are nonspecific to manganism (Beuter et al. 1994; 
Edwards and Beuter 1997; Pal, et al. 2001). 
 
Neurological examination will identify parkinsonism and dystonia, and help to differentiate PD 
and manganism. Both can have parkinsonian features including bradykinesia, rigidity, masked 
facies, speech disturbance, micrographia and gait disturbance. The presence of resting tremor, 
asymmetry, and a good response to levodopa support a diagnosis of PD. In contrast, manganism is 
supported by early onset of gait dysfunction with a propensity to fall backward (Huang et al. 1989; 
Olanow 2004). Tremor, when present, tends to be postural or kinetic rather than resting, as seen 
in IPD4 (Huang et al. 1989; Calne et al. 1994). Patients with manganese-induced parkinsonism 
also frequently experience characteristic forms of dystonia consisting of facial grimacing and/or 
plantar flexion of the foot, which interferes with gait and is known as "cock-walk" (Huang et al. 
1989, 1993, 1997, 1998; Rodier, 1955; Schuler et al. 1957; Mena et al. 1967; Tanaka and Lieben 
1969; Smyth et al. 1973, Yamada et al. 1986; Wennberg et al. 1991; Ky et al. 1992; Calne et al. 
1994; Chu et al. 1995; Hochberg et al. 1996; Mergler and Baldwin 1997; Pal et al. 1999). 
A compatible clinical picture must be present in the context of excessive exposure in order to have a 
possible case of manganism. The experts suggested that the most sensitive endpoint is neurological/ 
neuropsychological. The neuropsychological points of interest have already been described. A 
complete neurological examination by a neurologist specialized in movement disorders should 
confirm signs of parkinsonism (extrapyramidal manifestations) such as gait and speech 
disturbances, postural instability, bradykinesia, rigidity, micrographia and masked facies, which are 
consistent with classical manganism. Tremor, more rarely present than in IPD, tends to be postural 
rather than resting. 
These examinations, coupled with a complete occupational history, should lead to a provisional 
diagnosis. Neuro-imaging should take the diagnosis to the next level. 
 
Given the progressive nature of manganism, it is important to emphasize that, as stated in the 
introduction to this section, individuals should be followed and clinical data gathered dynamically 
and re-evaluated periodically. In doing so, the clinician will increase his confidence that a given 
case is indeed a case of manganism: from a single mild isolated neurological dysfunction 
accompanied by documented slight neuropsychological dysfunction that could be labeled as a 
possible case, towards a probable case where two or three of the neurological symptoms described 
earlier are better defined while neuropsychological tests showing abnormalities are starting to group, 
culminating in a typical neurological (extrapyramidal manifestations and dystonia) and 
neuropsychological picture from which a case can be labeled as clinically probable with confidence 
(Fiedler 1996; Mergler et al. 1999; Lucchini et al. 2000). As information is gathered, the physician 
may choose to reclassify the patient based on the new information.  
 
 
                                                 
4  Note that the classical clinical picture of IPD, showing much more frequent asymmetric alterations and tremor, is 
of resting nature. 
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 - Pharmacological response 
A challenge or therapeutic trial with levodopa is very useful in distinguishing IPD from other forms 
of parkinsonism. IPD typically responds well to L-dopa therapy and patients have a sustained 
benefit. In addition, chronic treatment is frequently associated with the development of motor 
complications (dyskinesia, motor fluctuations). However, movement disorders from manganism will 
show poor or unsustained improvement with a therapeutic trial of L-dopa (Lu et al. 1994) and 
levodopa-induced motor complications have not been described. This is because chronic manganese 
intoxication spares the nigrostriatal system and is thought to cause parkinsonism by damaging 
output pathways that are downstream from the nigrostriatal dopaminergic pathway (Shinotoh et al. 
1995). This absence of pharmacological response is one of the most widely cited key features in 
distinguishing manganism and other parkinsonism sharing the same physiologico-pathological 
mechanism as IPD (Huang et al. 1993; Calne et al. 1994) even if it is based on a limited number of 
reported cases in the literature. A similarly poor response to levodopa is seen in other parkinsonian 
disorders such as MSA and PSP. 
 - Imaging data 
Positive MRI (bilateral, symmetrical, high signal T-1 weighted images in the globus pallidus and to 
some extent in the substantia nigra pars reticulata) in an asymptomatic individual is indicative of Mn 
accumulation at its target organ (Newland et al. 1989; Nelson et al. 1993; Dietz et al. 2001). 
According to Hulka and Wilcosky (1988, 1990), this finding constitutes a biological marker of the 
effective dose in the Hulka’s classification. It does not, however, necessarily correlate with the 
development of manganism. Positive MRI in a symptomatic individual could be considered a 
manifestation of degeneration of the striatal / pallidal system (Hauser et al. 1994; Layrargues 1995). 
However, given the half-life of Mn in the brain, a negative result when the exam is performed more 
than 4-6 months after cessation of exposure is not conclusive (Kim et al. 1999). 
 
This test may be helpful in differentiating manganism from IPD and possibly other forms of 
parkinsonism (Shinotoh and Calne 1995).  In IPD patients, the striatum and pallidum appear normal 
on T-1 weighted images (Calne et al. 1994). However, with gray and white matter signal-
suppression inversion recovery sequences, signals from the substantia nigra pars compacta are 
abnormal in the majority of IPD patients (Hu e t  a l .  2001). The same author also concluded that 
this test was less reliable than fluorodopa positron emission tomography (F-dopa PET) scan in 
discriminating patients with moderately severe PD from normal subjects.  
 
T1-weighted signal hyperintensities can be associated with lipid, hemoglobin breakdown products, 
melanoma, neurofibromatosis, and calcification (Kim 2004), but they can usually be differentiated 
from manganese by the pattern of involvement and imaging with CT Scan and T2-weighted MRI.  
 
Striatal fluorodopa uptake on the fluorodopa positron emission tomography (F-dopa PET) scan, a 
measure of the functional integrity of the nigrostriatal system, is consistently reduced in IPD  
(Martin et al. 1989; Pal et al. 2001), especially in the posterior putamen (Caparros-Lefebvre et al. 
1998). The same test was normal in one series (4 cases) of highly probable cases of occupational 
manganism and in animals with experimentally induced manganese toxicity (Wolters et al. 1989; 
Kim et al. 1998, 1999). These findings have been confirmed in other cases with pictures strongly 
suggesting manganism (Kim et al. 1999; Abe et al. 1999).  The F-dopa PET scan is thus regarded as 
one of the most promising tools for excluding the diagnosis of IPD (Calne et al. 1997; Abe et al. 
1999; Kim et al. 1999; Piccini and Whone 2004). The nigrostriatal system is affected in most other 
forms of primary degenerative parkinsonism (MSA, PSP) and hence F-dopa PET is abnormal, 
differentiating these conditions from manganism (in addition to differences in clinical features etc). 
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Thus, a clinical picture of parkinsonism with no response to levodopa and a normal F- dopa PET 
scan strongly supports a diagnosis of manganese induced parkinsonism. Nevertheless, its 
specificity has yet to be confirmed in discriminating manganism from other causes of 
parkinsonism. In fact, it cannot be excluded that in more severe cases of manganism, the damage 
extends from the pallidum to the nigrostriatal system, causing abnormal F-Dopa uptake (Racette et 
al. 2005). This means that an abnormal F-Dopa PET scan would not exclude manganism. However, 
if all other forms of parkinsonism have been excluded by other means, a normal F-Dopa PET scan 
can support a definite case of manganism. PET requires substantially more validation before it can 
be widely recognized as useful in the differential diagnosis of manganism.  F-Dopa PET scan does 
not have a strong linkage to the clinical outcome of manganism and Ravina et al. (2005) do not 
support the use of radiotracer imaging in such conditions. 
 - Histopathological data 
 
Degeneration of dopaminergic neurons in the nigrostriatal pathway coupled with intracytoplasmic 
Lewy bodies and a loss of striatal dopamine are the pathological hallmarks of IPD (Calne et al. 
1994). IPD is also associated with degeneration and Lewy bodies in other regions, including the 
locus coeruleus, the nucleus basalis of Meynert, the hypothalamus, the dorsal motor nucleus of the 
glossopharyngeal and vagal nerves, as well as selected neurons of the cerebral cortex, spinal cord, and 
peripheral components of the autonomic nervous system (Olanow and Tatton 1999). 
 
The extranigral pathology in IPD may also be quite extensive, involving the dorsal motor nucleus of 
the glossopharyngeal and vagal nerves, subnuclei of the reticular formation and the raphe system, 
the coeruleus and subcoeruleus complex, the magnocellular nuclei of the basal forebrain, and many 
subnuclei of the thalamus and amygdala (Braak et al. 2003). 
 
In manganism, degenerative lesions were demonstrated in the globus pallidus and subthalamic 
nucleus, red nuclei thalami, caudate nucleus and the putamen, with less frequent and less severe 
injury to the substantia nigra pars reticulata. There are no Lewy bodies. Chronic exposure to 
excessive Mn leads to neuronal loss and gliosis in these basal ganglia structures together with 
characteristic astrocytic changes known as Alzheimer type II astrocytosis (McKinney et al. 2004; 
Normandin et al. 2002; Olanow 2004; Mergler et al. 1996).  
Histopathological studies in manganese-intoxicated animals reveal damage primarily in the globus 
pallidus, mainly gliosis and Alzheimer type II astrocytosis, with sparing of the substantia nigra pars 
compacta and striatal dopamine levels (Olanow et al. 1996). Glial cells are known to sequester Mn2+ 
by a high affinity transport mechanism (Aschner et al. 1999) and are considered to be the likely 
initial targets of manganese neurotoxicity (Spanger et al. 1998; Henriksson et al. 2000).  
These pathological findings form the basis for differentiating PD and manganism, for understanding 
the clinical, pharmacological and imaging findings, and are useful in confirming the diagnosis at 
post mortem. 
 
- Differential diagnosis 
Manganism must also be differentiated from other forms of parkinsonism as well as PD.  
 
In a possible case of occupational manganism, the clinician should gather clinical and para-clinical 
information that can exclude all of the other disorders in the differential diagnosis of parkinsonism 
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before any conclusion of probable or definite manganism is made. Of particular interest will be 
other causes of occupational parkinsonism (Tanner 1992). While many classifications and lists of 
those diseases exist, a classification published recently by Hobson is presented in Appendix D 
(Hobson 2003). For example, impaired vertical eye movements suggest progressive supranuclear 
palsy (PSP), impaired autonomic function suggests multiple system atrophy (MSA), impaired 
cerebellar function suggests olivopontocerebellar atrophy (OPCA), focal hand dystonia and cortical 
myoclonus or apraxia suggesting cortical basal ganglionic degeneration (CBGD). It is beyond the 
scope of this report to give details on the different criteria for the clinical diagnosis of each of these 
diseases; the reader can refer to the original article for further information. Many articles were 
devoted to the differential diagnosis of parkinsonism (Feldman 1992; Tanner and Aston 2000; Facca 
and Koller 2003; Hobson, 2003; Litvan et al. 2003; Mitra et al. 2003).  
 
 
 
 
 
IRSST Management of Occupational Manganism: 
Consensus of an Experts’ Panel 
 
 
 
19
MANDATE 4  
 
Propose the ideal avenue for establishing or invalidating the diagnosis of 
occupational manganism, taking into account the human and technological 
resources available in Québec5 
 
In this section, the objective is to specify which exam or test will be most useful for correctly 
diagnosing a case of manganism and to specify in which sequence intervene. 
 
 
Recommendations 
 
In order to diagnose a case of occupational manganism, the following avenue is proposed: 
 
Step 1. 
For a worker suspected of having occupational manganism, the occupational physician should 
perform a thorough evaluation of Mn occupational exposure along with an evaluation of the 
presenting clinical picture. 
A) He should first perform a thorough clinical case history that includes: 
o The history of current clinical symptomatology 
o The history of past clinical problems 
o The family history 
B) He then performs a complete physical examination with an emphasis on the neurological 
examination to identify clinical signs of parkinsonism.  
C) The physician should detail occupational exposure to any neurotoxic contaminants. Starting with 
an occupational history, he will search work records indicating Mn exposure and specific work 
assignments known to be associated with Mn exposure. He will also gather data, past or present, 
from occupational hygiene investigations (whenever these exist).  
D) If the occupational physician deems it appropriate, he could gather basic neuropsychological data 
using a standardized questionnaire and/or a short battery of tests. 
E) Complementary investigations: liver testing and complete blood count (CBC), iron stores6. 
Depending on the temporal relationship between the time of the Mn exposure and the 
examination, blood and urine Mn levels and an MRI could be ordered as well as other pertinent 
tests (e.g., blood copper, ceruloplasmin, neuroacanthocytes, etc.), depending on the clinical 
history. 
After this initial data collection, the occupational physician could then refer the worker to a 
neurologist specialized in movement disorders if further exploration is deemed to be appropriate. 
 
                                                 
5 The following recommendation also takes into account Québec’s specific occupational medicine structure and 
accessibility to different resources 
6  Depending on the results of the CBC. 
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Consensus status 
 
These recommendations were agreed upon by consensus .  
 
 
Step 2. 
A neurologist knowledgeable in movement disorders should assess the patient to determine if the 
clinical picture is consistent with a diagnosis of manganism. Tests and procedures required to 
determine the correct diagnosis should be ordered as appropriate. 
 
Step 3. 
Complementary investigations could include: 
o Formal neuropsychological evaluation 
o MRI, if not already done and appropriate time-wise since cessation of exposure to Mn 
o L-dopa trial 
o Fluorodopa PET scan or other imaging study to assess the integrity of the nigrostriatal 
system.  
Based on these assessments, the neurologist will determine if in his opinion a given case suffers 
from clinically possible, probable or definite manganism. The diagnosis may be modified based on 
subsequent examinations and the acquisition of further information. 
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Rationale 
 
Step 1      
           
In Québec, an occupational physician is responsible for a given workplace. He is in charge of the 
development and execution of a specific health program for each given workplace. As such, his 
knowledge of the settings makes him ideally suited to do the initial investigation of workers 
suspected of manganese intoxication (Levy and Nassetta 2003).   
 
Workers showing suspect symptoms of manganese intoxication should be investigated initially for 
both the magnitude of exposure and clinical status.  
 
It is possible that cumulative lifetime exposure to Mn contributes to the likelihood that the patient 
will develop manganism. Two situations should be considered: a short-term high intensity exposure 
or long-term chronic overexposure to lower levels of Mn. It is thought by some that overexposure is 
more likely to occur after long-term chronic exposure; therefore, information on all aspects of 
exposure must be collected. An accurate job description is also important since exposure levels can be 
very different depending on the different tasks a worker performs. In the case of a welder, 
information on welding rods and the materials used is important, particularly regarding manganese 
content. Information on ventilation and personal protective devices must also be collected. Other 
possible neurotoxic exposures should be documented as they might also induce parkinsonism or 
chronic toxic encephalopathy (Wennberg 1994). A list of neurotoxic substances is presented in 
Mandate 6. Quantitative data on manganese exposure in the occupational environment determined 
by industrial hygiene investigation and surveillance is of utmost importance when available. If not, 
qualitative data may be helpful and yield significant information. Unfortunately, past exposure data 
are often unavailable.  
 
Blood and urine Mn sampling has been used to reflect recent exposure. Although more usable as a 
group value than as an individual value, it can nonetheless prove informative if consistent with 
environmental data (Luse et al. 2000).  
 
One way to assess the accumulation (via overexposure or decreased clearance) of manganese in the 
basal ganglia is by a brain T-1 weighted MRI. It would show bilateral, usually symmetrical 
hyperintensities in the globus pallidus if done during exposure or within 4-6 months after cessation 
of overexposure. This result is to be considered as a biological biomarker for Mn accumulation in 
the basal ganglia but not necessarily intoxication. 
 
An additional way to try and assess manganese body burden is by the chelation test, which is a way 
of assessing the overall amount of manganese in the body. This test has to be considered 
investigational until clear normal values are established. 
 
Regarding clinical aspects, neurological and psychiatric signs and symptoms of manganism should 
be evaluated, including extrapyramidal disturbances, dystonia, tremor and aggressive components of 
mood. Particular attention also has to be paid to the worker’s personal and familial clinical history. 
A list of personal and family diseases likely to cause or be associated with parkinsonism is 
presented in the differential diagnosis section above. Other pertinent questioning and testing by the 
occupational physician can be based on including conditions in, or eliminating them from this list in 
the differential diagnosis of parkinsonism. If the physician finds a case with possible parkinsonism, 
he should consult the list of parkinsonian syndromes and ask pertinent supplementary questions 
and/or perform appropriate tests to try and determine whether the patient suffers from one of these 
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conditions rather than manganism. Some of these conditions can be screened out almost 
immediately by a good medical questionnaire for medication, drug use or abuse, age of the patient, 
history of occupational exposure and findings on examination. Others can be screened with blood 
tests or genetic testing. Most importantly, if a patient is thought to have parkinsonism, the patient 
should be referred to a neurologist with expertise in movement disorders. 
 
Some functional neuropsychological tests (finger tapping, Luria-Nebraska motor tasks, symbol 
digit and digit span), related more specifically to impairment of neurosensorial response, motor 
function and memory, show abnormal results early in patients with Mn chronic exposure. These 
tests detect abnormal hand-eye coordination, hand steadiness and simple visual reaction time 
(Iregren 1992, 1999; Lucchini et al.  1995, 1999; Mergler et al.  1997; Roels et al .  1987, 1992, 
1999). The occupational physician might decide to administer the neuropsychological tests 
proposed in Appendix A.  
 
Steps 2 and 3 
 
As noted by the experts, a diagnosis of manganism is mainly a diagnosis of exclusion in a patient 
with parkinsonism and a history of exposure. This means that this diagnosis is accepted when other 
diseases that would produce a similar clinical picture are excluded. The neurologist will have to take 
steps to exclude these other diseases from his differential diagnosis list.  
 
Since IPD is present in about 3% of the population, diseases with parkinsonian symptoms and 
signs, including manganism, must first be differentiated from idiopathic PD (Shinotoh and Calne 
1995). Manganism may be difficult to differentiate from IPD in the early stages, but with time it is 
usually possible to separate these conditions based on the clinical picture, response to levodopa, 
development of motor complications, and imaging studies (Olanow 2004; Poewe and Wenning 
2002; Wolters et al. 2000; Pal et al. 2002). As PD is a relatively common disorder and many 
individuals have welded, it is possible that PD may develop in a person who has a history of 
manganese exposure. It is also possible that IPD and manganism may coexist in the same 
individual (Racette et al. 2001).  Some criteria pertinent to other parkinsonian disorders such as 
impaired vertical eye movements, orthostatic hypotension, cerebellar signs, cortical apraxias and 
myoclonus may help to establish the correct diagnosis  (Hobson 2003; Litvan et al. 2003). 
 
Further data to help in establishing a diagnosis can be obtained by using a more formal 
neuropsychological battery of tests than the one suggested at the beginning of this section (See 
Appendices B and C). 
 
As stated earlier, a therapeutic trial with levodopa is very useful in distinguishing IPD from 
manganism and other forms of parkinsonism. In manganism, a patient will show a poor or an 
unsustained response after levodopa treatment. It is important to note that, in order to correctly 
assess an improvement in clinical symptoms, these have to be easily assessed; consequently, this 
trial is of most value in the presence of clearly defined parkinsonian features. Also, it is important to 
ensure that an adequate trial of levodopa (time and dosage) has been employed. 
 
Striatal fluorodopa uptake on PET, a measure of the functional integrity of the nigrostriatal system, 
is consistently reduced in PD, especially in the posterior putamen, but exams were normal in a series 
of 4 patients with highly probable occupational manganism (Wolters et al. 1989). Similar normal F-
Dopa PET results have been reported in other patients with manganese induced parkinsonism (Abe 
et al. 1999; Kim.et al. 1999). In addition, F-Dopa PET studies were normal in primates rendered 
parkinsonian by manganese intoxication. Further, post mortem studies in patients and animals 
demonstrate preservation of the nigrostriatal system following manganese intoxication (Yamada et 
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al. 1986; Olanow et al. 1999). The F-dopa PET scan is thus regarded as one of the most promising 
tool for excluding IPD and other causes of parkinsonism but its specificity has yet to be confirmed 
in larger cohorts. It could thus become the “de-facto” gold standard for establishing definite 
manganism when all other causes of parkinsonism have been excluded by other available tests. 
 
As already discussed (p. 15-16), the specificity of the PET scan imaging has yet to be confirmed in 
its capacity to discriminate manganism from other forms of parkinsonism. In fact, it cannot be 
excluded that in more severe cases of manganism, the damage extends from the pallidum to the 
nigrostriatal system, causing abnormal F-Dopa uptake (Racette et al. 2005). This means that an 
abnormal F-Dopa PET scan would not exclude manganism. However, if all other forms of 
parkinsonism have been excluded by other means, a normal F-Dopa PET scan would confirm a 
definite case of manganism. PET requires substantially more validation before it can be widely 
recognized as useful in the differential diagnosis of manganism.  F-Dopa PET scan does not have a 
strong linkage to the clinical outcome of manganism and Ravina et al. (2005) do not support the use 
of radiotracer imaging in such conditions. 
 
In fact, since manganese-induced high signals usually disappear within one year following cessation 
of exposure, the F-Dopa PET scan or dopamine transporter signal-photon emission computed 
tomography [123I] β-CIT SPECT should be obtained in order to discriminate between IPD and 
manganism, especially if the worker presents signs of parkinsonism or neuropsychological 
disturbances more specific to basal ganglia origin, in the context of a normal T1-weighted MRI and 
more than six months after withdrawal from the source of Mn accumulation in the brain.  
 
Toxic substances that affect the basal ganglia and spare the nigrostriatal system are known: they are 
carbon monoxide (CO) intoxication (mostly acute, affects the putamen); cyanide (CN) intoxication 
(mostly acute, mostly the putamen and globus pallidus and sparing the substantia nigra); long-term 
exposure to carbon disulfide (CS2) may produce a form very similar to manganism or MSA but, 
most of the time, would cause pyramidal signs, cerebellar ataxia as well as axonal polyneuropathy; 
the brain MRI would show hyperintensity lesions in T1-weighted images in the subcortical white 
matter, basal ganglia and brain stem through microangiopathy (Ku et al. 2003). Finally, there is 
neuro-intoxication with MPTP. This drug specifically affects the dopamine neurons and has clinical 
pharmacologic and imaging features different from manganese intoxication. All of these causes of 
toxic parkinsonism are extremely rare. 
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MANDATE 5 
 
Propose a medical follow-up and treatment plan for workers with 
occupational manganism 
 
Recommendations 
           
          The experts agreed that there was no specific treatment plan for manganism. Antiparkinsonian drugs 
may have a positive effect on parkinsonian symptoms and signs, but this effect is temporary and of 
short duration if present at all. Antioxidants have been recently studied but benefits have not been 
proven. Chelation is still considered investigational. Symptom relief and rehabilitation therapies are 
all that remain. 
 
The main intervention consists of stopping significant exposure to manganese as well as other 
recognized neurotoxic agents as soon as possible, when the symptoms and signs may still be 
reversible. 
 
The experts also agreed on medical monitoring plan in the first year and later as appropriate. If a 
change is seen in the worker’s condition, then the diagnosis can be reviewed as in Mandate 4. 
 
 
 
 
 
Consensus status 
 
These recommendations were agreed upon by consensus.
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Rationale 
 
- Treatment 
 
As already mentioned, “Manganese neuro-intoxication is classically associated with Mn 
accumulation in, and damage to, the globus pallidus, striatum and substantia nigra pars reticularis 
with relative sparing of the nigrostriatal system” (Olanow 2004; Yamada et al. 1986). 
 
Neuropsychological disturbances related to basal ganglia origin are mainly motor and characterized 
by deficits in attention allocation and filtering, implicit learning and memory, leading usually to 
acquisition of behaviours and efficiency in working memory by motor learning, sequencing and 
movements (Ring et al. 2002). 
 
At an early stage, neuropsychiatric disturbances could be the presenting picture. 
 
Even though it is known that manganese is a cellular intoxicant that may damage nerve impulse 
transport systems, enzymatic activities and receptor functions, the exact way that manganese 
neurotoxicity occurs has not yet been clearly established (Aschner and Aschner 1991). It cannot be 
concluded that one simple dysfunction is the basic mechanism of manganese neurotoxicity. It 
appears more probable that the basic mechanism is multifactorial, involving oxidative stress induced 
by iron and the direct interaction of manganese with the mitochondria in the terminal part of the 
dopaminergic neurons, leading to selective mitochondrial dysfunction and resultant excito-toxicity 
(Verity 1999). Mn exposure leads to accumulation of Mn in the pallidum and striatum, and this is 
likely why these areas are most prominently affected in manganism. In manganism, extrapyramidal 
parkinsonian signs may appear with rigidity, slowness, gait disturbance, and micrographia. They are 
similar to, but not identical to IPD. 
 
Based on the hypothesis that free radicals, oxidative stress, and mitochondrial dysfunction 
contribute to Mn-induced cell damage, antioxidant agents (Fendyur et al. 2004) and co-enzyme Q10 
have been considered as potentially providing benefit for patients with manganism (Horvath et al. 
2003; Andersen et al. 2001; Ravina et al. 2003; Shults et al. 2002).  
 
Anti-parkinsonian drugs have been tested in patients with manganism symptoms but are usually 
ineffective. Any positive effects are generally limited and of short duration. Some authors have 
attributed these temporary benefits to the placebo effect (Lu et al. 1994). Positron emission 
tomography studies have recently shown that the placebo effect is related to the activation of the 
limbic circuitry by different neurotransmitters and neuropeptides, perhaps disease-specific, involved 
in modulating the activity of the limbic system (De La Fuente-Fernandez et al. 2004).  
 
Chelation therapy, mainly using CaNa2EDTA, has been used with reports of variable success in 
acute and chronic cases of manganese intoxication (Discalzi et al. 2000; Hernandez et al. 2002; 
Komaki et al. 1999; Fitzgerald et al. 1999). There are some reports of improvement with chelating 
treatment and cessation of exposure but, there have been no controlled trials and the treatment is 
still controversial. Further, it can be complicated by kidney damage. For now, chelation therapy is 
still considered investigational. 
 
The main treatment therefore consists of stopping exposure in the early phase of the illness, when 
the signs and symptoms first appear and may be reversible. This requires detection for the early 
signs; these are detected as early neurofunctional changes, mainly motor. 
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Workers should also be prevented from harmful occupational exposure to other recognized 
neurotoxic agents like organic solvents, carbon disulfide, carbon monoxide, cyanide, mercury, lead, 
etc. (see Mandate 6 for a more complete listing). 
 
Supportive treatment is recommended for any associated sleep problems, mood disturbances, loss of 
libido, etc. Psychological, cognitive behavioural, physical, speech and occupational rehabilitation 
therapies should be offered as appropriate. 
 
Treatment outcomes can be measured by subjective rating of therapy satisfaction and also by the 
usual psychosocial or psychometric tests; some scales can also be useful: “Activities of Daily 
Living” (ADL) and the motor components of UPDRS for assessment of neurofunctional motor 
disturbances. However, none of these tests has been validated in manganism. 
 
Since liver diseases, anemia, and alcoholism can affect manganese accumulation in the brain, these 
conditions should be looked for and treated. 
 
Surgical interventions used in IPD have not been shown to be of value in manganism. 
 
 
- Medical monitoring 
 
Special attention should be given to follow-up of the evaluation of the worker during the first year 
following the diagnosis. Clinical features of manganism may worsen or improve following 
withdrawal from the source of exposure. For this reason, the assessment of permanent deficit should 
be deferred for at least a year. 
 
The physician in charge can do this monitoring, with referral to specialists if there are signs of 
significant deterioration or change in the progression of the disease.  
 
After the first year, the following examinations should be performed annually: 
o Neurological assessment 
o Neuropsychological assessment. These tests should not be used too frequently, as learning 
effect may confound the interpretation. One could use alternate forms 
o Functional capacities assessment 
o Biological testing: CBC, Blood Mn, iron stores, liver functions 
 
Again, if any negative change occurs in the worker’s condition, a multidisciplinary decision as to 
the treatment, the anatomo-physiological permanent deficit impairment and rehabilitation should be 
taken. 
 
Although work-related neurotoxic risks today rarely reach the level of the pathologies of previous 
decades, exposure to manganese may still cause changes in certain higher brain functions. The 
corollary is that a series of tests should be assembled that defines the cerebral functions that are 
affected as a consequence of chronic exposure to manganese.  
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MANDATE 6  
 
Propose safe conditions for keeping workers with manganism at work or for 
returning them to work  
 
Recommendations 
A worker considered as a definite, probable or possible case of occupational manganism and who 
has the physical capacity to work should be kept from any further significant exposure to 
manganese in the workplace. Furthermore, he should not be returned to a workplace significantly 
contaminated with any other recognized neurotoxic agent. The level of Mn exposure should be as 
low as possible but never exceed 0.03 mg Mn/m3 (expressed as respirable dust).  
 
 
 
Consensus status 
 
These recommendations were agreed upon by consensus. 
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Rationale 
As already discussed in this report, chronic Mn exposure may lead to serious damage of the central 
nervous system, called manganism. Manganism is a progressive and debilitating syndrome that 
typically begins with relatively mild nonspecific symptoms that gradually develop.  It has been 
suggested that the health effects, particularly on the central nervous system, occur in a “continuum 
of dysfunction” which could be dose-related (Mergler et al. 1999; ATSDR 2000; ACGIH 2001). 
Mergler et al. (1999) have described neurofunctional alterations attributed to manganese in workers 
who were otherwise asymptomatic and neurologically intact. There is a concern that these workers 
are at increased risk of developing manganism whose progression depends on the exposure level, 
the exposure duration and individual susceptibility. 
 
Furthermore, epidemiological studies suggest that lifetime cumulative exposure is the best indicator, 
allowing correlation of occupational exposure with the early effects observed on the CNS (Chandra 
et al. 1981; Roels et al. 1987a and b, 1992; Iregren 1990, 1992; Chia et al. 1993a and b; Mergler et 
al. 1994; Lucchini et al. 1995, 1999; Sjögren et al. 1996; Gibbs et al. 1999; ATSDR 2000; Ostiguy 
et al. 2003). For this reason, it is suggested that a worker who has shown CNS effects be given a 
work assignment removed from further significant Mn exposures. 
 
Few scientific data are available on the reversibility of the neurotoxic effects associated with 
chronic Mn overexposure. The researchers believe that the effects are rather irreversible (Ellenhorn 
and Barceloux 1988). However, there is some evidence that recovery may occur when the exposure 
stops (Smyth et al. 1973). Antiparkinson drugs such as levodopa may be able to reverse some of the 
neuromuscular signs of manganism (Ejima et al. 1992; Rosenstock et al. 1971), but these drugs 
have several side effects, and reports indicate that they do not improve the patients’ neurotoxic 
symptoms (Calne et al. 1994; Chu et al. 1995; Cook et al. 1974; Ellenhorn and Barceloux 1988; 
Haddad and Winchester 1990; Huang et al. 1989). The ATSDR review (2000) reports that 
symptoms of manganism can be improved by certain medical treatments, but the improvement is 
generally temporary and damage to the brain permanent. 
Huang et al. (1993, 1998) documented the progression of manganism in five workers chronically 
exposed to Mn in the ferroalloy sector.  Their results show that the disease continues to progress 
even 10 years after leaving the workplace. Roels et al. (1999) carried out an eight-year longitudinal 
study on the same cohort as that published in 1992 in order to determine the reversibility of three 
early neurotoxic effects: hand-eye coordination (HEC), hand steadiness (HS), and simple visual 
reaction time (SVRT). They concluded that the tests used were reproducible and reliable throughout 
the study. They also demonstrated that past severity of Mn exposure determined the relative 
significance of the loss in precision in hand and forearm movement (HEC) in exposed workers as 
compared to the control group as well as their recovery potential. However, for the two other tests, 
HS and SVRT, no recovery was noted, suggesting that these conditions are irreversible.  
 
However, when neurological damage is measured, it could be reversible but could also worsen over 
time, even in the absence of occupational exposure.  As a result, it is important to intervene as 
rapidly as possible, in a phase that is possibly still reversible.  Then, any significant additional 
exposure to manganese or to any other neurotoxic agent could contribute to the acceleration in the 
progression of the disease.  
 
At the present time, a dose-response relationship cannot be established from all the epidemiological 
studies available, but early signs of central nervous system injury by inhalation have been observed 
at levels from 0.027 to 1.0 mg Mn/m3 in total dusts (Chia et al. 1993a, 1993b, 1995; Iregren 1990; 
Lucchini et al. 1995; Mergler et al. 1994; Roels et al. 1987a, 1992; Wennberg et al. 1991), while 
IRSST Management of Occupational Manganism: 
Consensus of an Experts’ Panel 
 
 
 
31
cases of manganism have been reported at levels as low as 2 to 22 mg/m3 in total dusts (Cook et al. 
1974; Rodier 1955; Saric et al. 1977; Schuler et al. 1957; Tanaka and Lieben 1969; Whitlock et al. 
1966). These neurotoxic effects were observed following exposures varying from 1 to 35 years 
(Schuler et al. 1957; Whitlock et al. 1966; Tanaka and Lieben 1969; Cook et al. 1974; Saric et al. 
1977; Roels et al. 1987a, 1992; Iregren 1990; Wennberg et al. 1991; Chia et al. 1993a, 1993b, 1995; 
Mergler et al. 1994; Lucchini et al. 1995). In the case of manganese, Roels’ studies, which were 
corroborated by several other studies, are the ones most commonly used, and the majority of the 
organizations use these results as a basis for proposing limit values based on their respective 
approaches. 
 
Because of the continuous progression of the disease in most cases, a diagnosed worker, even at the 
possible stage, should be kept away from any significant additional exposure. In 2003, the IRSST 
and CSST established an interim level of 0.00015 mg/m3 in total dusts, for clinically probable and 
definite cases of manganese-induced parkinsonism, which is the WHO recommended level for the 
general population including newborns and elderly people. This interim level was established while 
waiting for the expert panel to recommend a more applicable but still safe level of exposure. 
 
In 2000, the American Agency for Toxic Substances and Disease Registry (ATSDR) established a 
concentration at which no effect (NOAEL) should occur on the CNS or pulmonary system of 
healthy workers.  This level is 0.07 mg Mn/m3 in respirable dust and represents an average exposure 
level for a healthy worker.  
 
Based on the level of scientific knowledge and for practical reasons, the experts agreed on the 
following recommendations for keeping workers with manganism at work or for returning them to 
work when medical conditions permit: the occupational exposure to manganese should be kept as 
low as possible and should be accompanied by a ceiling value, a value never to be exceeded of 0.03 
mg/m3, measured in respirable dusts. This value is based on the ATSDR established NOAEL. The 
ATSDR value of 0.07 is divided by 2 and, rather than being an average value for the work shift, it is 
converted to a ceiling value.  Since the ATSDR level has been established for healthy workers, the 
experts concluded that half this value, 0.03 mg/m3, evaluated in respirable dusts and never to be 
exceeded should not be detrimental to the health of the confirmed (definite and probable) or 
suspected (possible) diseased worker and should be applied to all those cases where medical 
diagnosis is such that the worker is judged capable of returning to or staying at work. 
 
The experts also concluded that workers who show some effects of manganism should not be 
exposed to other neurotoxic agents in the workplace. Human neurotoxicity has already been 
documented for many chemicals (Costa and Manzo 1998). These substances include metals, 
solvents, pesticides, gases, and other miscellaneous substances. The metals most frequently 
associated with neurotoxicity are aluminum, arsenic, lead, manganese, mercury, thallium, trimethyl 
tin and welding fumes. Many solvents have shown different effects on the central nervous system: 
carbon disulfide, n-hexane, methanol, methyl n-butyl ketone, perchloroethylene, styrene, toluene, 
trichloroethylene, 1,1,1-trichloroethane, etc., as did many pesticides including carbamates, 
chlordecone, chlorophenoxy compounds, cyclodienes including chlordane and aldrin, 
dithiocarbamates and organophosphates. 
 
Many gases such as carbon monoxide, ethylene oxide, cyanide, hydrogen sulfide, methyl bromide, 
methyl chloride, nitrous oxide, waste anesthetic gases. Other miscellaneous substances (allyl 
chloride, acrylamide, dimethylaminoproprionitrile, methyl methacrylate, naphthalene, 
trinitrotoluene) have also been documented for neurotoxic effects. 
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MANDATE 7 
 
Evaluate the relevance of a monitoring and/or early screening and 
intervention program for asymptomatic workers exposed to manganese.  
Should such a program prove to be relevant, propose an operational strategy 
that includes defining the target population, organizing follow-up, establishing 
positivity criteria, and selecting appropriate interventions 
 
Recommendations 
 
There is a consensus for considering clinical manganism as a condition that could severely decrease 
the quality of life of affected individuals, their ability to work and to fulfil their social role. It is 
recognized that manganism is a progressive disorder ending up in a severe neurological and 
neuropsychological impairment.  
 
A wide variety of neuropsychological tests have been used in studies of groups of asymptomatic 
individuals exposed to low doses of manganese. These tests are considered to be safe and acceptable 
for workers, affordable and relatively easy to perform. The distribution of values in normal 
populations not exposed to neurotoxic substances is usually known, and the metrologic 
characteristics of these tests in terms of precision and reliability have been evaluated.  Functional 
tests are considered to be sensitive indicators of the early neurotoxic effects of Mn. On the other 
hand, the quantitative relationship between the prevalence rate of abnormal test results and the 
duration and intensity of different types of environmental exposures to manganese is not precisely 
known.   
 
None of these functional tests is specific to the neuropsychological effects of manganese, and 
abnormal results have been associated with other adverse environmental exposures. However, a 
consistent pattern of abnormalities has been associated with manganese, including deterioration of 
the rapidity of neurosensorial response, motor function, mood and memory tests.  There is no data 
from longitudinal studies allowing an assessment of the value of any test or combination of tests for 
predicting the occurrence of clinical manganism. On an individual basis, it is therefore impossible to 
predict who among asymptomatic workers exposed to low doses of manganese and having some 
abnormal functional tests will develop a syndrome of clinical manganism. Based on current 
scientific knowledge and the criteria of the WHO to be fulfilled in order to implement screening 
program and therefore good medical practice, no recommendation can be made for a screening 
program targeting asymptomatic workers exposed in the workplace. A prospective longitudinal 
controlled study could be useful for learning more about the progression from pre-manganism or 
some preclinical effects of Mn to clinical manganism.   
 
However, in research settings, neuropsychological tests may be useful at the group level, in order to 
better describe the natural history of pre-manganism, to establish occupational exposure guidelines 
and permissible levels, and to identify plants, jobs and categories of workers at risk in conjunction 
with environmental monitoring biomarkers. The only preventive intervention that could be proposed 
to reduce or eliminate the risk of developing clinical manganism is the reduction of exposure. 
 
Consensus status 
 
These recommendations were agreed upon by consensus. 
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Rationale 
 
A screening program aiming to detect an asymptomatic person and to implement preventive 
measures, should meet the following criteria:   
o The disease burden is important 
o The natural history of the disease including a preclinical stage 
o There is a screening test (or battery of tests) that is safe, acceptable, easy to perform, 
affordable, precise and reliable  
o The distribution of values for the test in the normal and risk population is known 
o There is a cut-off level providing acceptable sensitivity (capacity to predict disease 
occurrence, specificity (capacity to exclude disease occurrence), and predictive positive value 
(proportion of individuals who will develop the disease among those having a positive test) 
o There is an effective intervention at the preclinical stage that could reduce or eliminate disease 
risk or alter the course of the disease 
 
Manganism is a condition that reduces the quality of life of affected individuals and their ability to 
work and to fulfil their social role.  Furthermore, at clinical stage, some effects are irreversible, and 
the disease may progress towards severe manganism, even if exposure is drastically reduced by 
removing the affected individual from the workplace (Huang et al. 1993, 1998).   
 
There is no prospective follow-up study describing the evolution of manganism from the preclinical 
to the clinical stage.  The early natural history of manganism has to be reconstructed from cross 
sectional studies of individuals exposed to various levels and durations of manganese exposure, and 
from interviews with individuals with clinical manganism.  It is generally recognized that the central 
nervous system effects of manganese progressively develop along a continuum of dysfunction, 
starting with subtle neurofunctional disturbances, evolving initially towards subclinical neurological 
signs, and thereafter towards the clinical neurological and psychiatric manifestations of manganism 
(Mergler et al. 1999; ATSDR 2000; ACGIH 2001).   
 
A wide variety of neuropsychological tests have been used in epidemiological studies of different 
groups of asymptomatic individuals exposed to low doses of manganese. These studies have been 
described in detail elsewhere (Ostiguy et al. 2003) and are listed and some are described in Mandate 
6 of this report (Chandra et al. 1981; Roels et al. 1987a and b, 1992; Iregren 1990, 1992; Chia et al. 
1993a and b; Mergler et al. 1994; Lucchini et al. 1995, 1999; Sjögren et al. 1996; Gibbs et al. 1999; 
ATSDR 2000).      
 
Among the other available studies, Bowler et al. (2003) compared the neuropsychological function, 
emotional status, and psychoneurological symptoms of 76 former and current chemical industry 
welders primarily involved in steel welding. The welders performed worse than the controls on tests 
of verbal learning, working memory, cognitive flexibility, visuomotor processing speed, and motor 
efficiency. They had poorer colour vision and emotional status, and an increased prevalence of 
illnesses and psychiatric symptoms. Within the group of welders, the number of hours welding was 
negatively related to scores on verbal learning, auditory span, working memory, cognitive 
flexibility, and motor efficiency.  All the functional tests that were used in the above-mentioned 
studies are considered to be safe and acceptable for workers. Sophisticated and very expensive 
technologies are not required and the tests are relatively easy to perform by experienced technicians. 
Results are generally expressed as a continuous score or ordinal scale. The distribution of values in 
(normal) populations not exposed to neurotoxic substances is usually known, and abnormal results 
are defined as a deviance from a mean, median or modal value, either on the basis of a selected 
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percentile or a standard deviation. The metrologic characteristics of these tests in terms of precision 
and reliability were also evaluated.  
 
For some tests, significantly higher than expected rates of abnormal results have been reported for 
exposure concentrations in the air as low as 0.027 mg Mn/m3 in total dust (Lucchini et al. 1995). All 
these functional tests are generally considered as being sensitive indicators of the early neurotoxic 
effects of manganese (Mergler et al. 1997; Iregren 1999).  However, the quantitative relationship 
between the prevalence rate of abnormal test results and the duration and intensity of different types 
of environmental exposures to manganese is not precisely known.   
 
None of these functional tests is specific to the neuropsychological effects of manganese.  Although 
there is some inconsistency in the results of the above-mentioned studies, the most consistent 
(specific) pattern of abnormalities includes deterioration in the rapidity of neurosensorial response, 
motor function, and memory tests (Iregren 1992, 1999).   
The value of these tests in predicting the occurrence of clinical manganism is not documented.  To 
date, only one long-term follow-up study of asymptomatic exposed workers has been conducted 
and the results published. Roels et al. (1999) carried out an eight-year longitudinal study on the 
same cohort as that published in 1992 in order to determine the reversibility of three early 
neurotoxic effects: hand-eye coordination (HEC), hand steadiness (HS), and simple visual reaction 
time (SVRT). They found some recovery in precision in hand and forearm movement after the 
implementation of better exposure controls or removal from exposure. No recovery was noted for 
HS and SVRT. Despite the fact that two of these conditions seem irreversible, the authors do not 
suggest any of the tests as predictive of the development of manganism because none of the 
workers had or developed clinical features of manganism. On an individual basis, it is thus 
impossible to predict who among asymptomatic workers exposed to manganese and having some 
abnormal functional tests will develop a syndrome of clinical manganism.     
 
The majority of cases of manganism reported in the literature came from operations in mines where 
concentrations were extremely high and could reach 900 mg Mn/m3 (Flinn et al. 1990; Rodier 1955) 
or in foundries (Whitlock et al. 1966; Smyth et al. 1973).  
 
Schuler et al. (1957) documented chronic Mn poisonings in chronically-exposed miners and in 
which one third of the air samples exceeded 5 mg Mn/m3. The latency period varied from a few 
months to a few decades. Tanaka and Lieben (1969) reported 7 cases of manganism and 15 cases at 
the diagnosis limit in 144 workers exposed to manganese dusts or fumes at concentrations above     
5 mg Mn/m3. In the literature, no proven case of clinical manganism has been reported for exposure 
levels below 2 mg Mn/m3 (Cook et al. 1974; Rodier 1955; Saric et al. 1977; Schuler et al. 1957; 
Tanaka and Lieben 1969; Whitlock et al. 1966). Neurotoxic effects were observed following 
exposures varying from 1 to 35 years (Schuler et al. 1957; Whitlock et al. 1966; Tanaka and Lieben 
1969; Cook et al. 1974; Saric et al. 1977; Roels et al. 1987a, 1992; Iregren 1990; Wennberg et al. 
1991; Chia et al. 1993a, 1993b, 1995; Mergler et al. 1994; Lucchini et al. 1995). 
 
The only preventive intervention that could be effective in reducing the risk of developing clinical 
manganism is a reduction of exposure. In the above-mentioned study of battery plant workers 
(Roels et al. 1999; Crump et al. 1999), ambient exposure to manganese was reduced during follow-
up.  Comparison of workers exposed to the lowest range of initial doses and staying in the 
workplace and individuals who left the company did not reveal any difference in outcome.   
 
Since there is no evidence of any specific manganese-screening tool, and as we know about the 
potential adverse consequences that may be associated with a “positive” label, no recommendation 
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can be made for a screening program targeting asymptomatic workers exposed in the workplace. 
However, neuropsychological tests may be useful at the group level, in order to describe the natural 
history of pre-manganism, to establish occupational exposure guidelines and permissible levels, and 
to identify plants, jobs and categories of workers at risk in conjunction with environmental 
monitoring of manganese concentration in dust and air, and measures of exposure biomarkers in a 
research setting.  Such a study should be performed on an ad hoc basis and the results could be kept 
anonymous, with only aggregated data divulged.    
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CONCLUSION 
 
The IRSST and the CSST are very grateful to the experts on the panel who invested a lot of time and 
effort to reach consensus on the seven questions that were prepared by the medical committee. Consensus 
has been reached in all situations.  
 
Occupational manganism has been clearly defined and a severity scale has been proposed. Criteria have 
been established for the classification and diagnosis of occupational manganism. A plan has also been 
proposed for the monitoring and treatment of patients. Finally, early screening for asymptomatic workers 
has not been recommended. Once a worker has been diagnosed with manganism, his exposure to 
manganese or other neurotoxic substances should be kept as low as possible. Prevention by decreasing the 
occupational exposure to manganese remains the best approach to prevent the development of the disease. 
 
From this very valuable information on medical aspects, and from additional work that has been done in 
Québec to document the occupational exposure of workers to manganese, it will be possible to better 
manage what now seems to be an emerging problem since only two compensation claims came to the 
CSST before the recent cluster of cases. 
 
Diagnosis should be easier to establish and the management of diseased workers will be greatly facilitated. 
CSST compensation parameters and management procedures for cases should be reconsidered taking into 
account the information included in the present report.  
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APPENDIX A:  Short neuropsychological battery of tests 
 
Function Test Duration (min) 
Mini Mental State Examination  5  
Verbal fluency COWAT 4  
Cognitive flexibility & Info 
processing 
Stroop Color Word & 4  
Divided attention Auditory Conson. Trigrams 4  
Information processing & set 
shifting 
Trails A & B 5  
Digit Span Digit Span 3  
Verbal learning Word Lists 5  
Motor speed Finger tapping 3  
Tactile ability Grooved Pegs 2  
Gross motor tactile Santa Ana 3  
Grip strength Dynomameter 1  
Graphic tremor Parallel Lines Tremor 2  
Tremometer 9 Hole Tremor Test 3  
Visuo-spatial, perceptual motor Digit Symbol 2  
Planning and organizing and 
Imm. Recall 
Rey Osterreith Copy 3 
Rey – 15 items  1  
Verbal memory Word lists 5  
Visual Attention Test Battery 
(computer administered) 
 10-12  
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APPENDIX B: Thorough neuropsychological battery of tests 
 
Domain Function Test Duration 
(min) 
Motor Coordination Santa Ana 5 
 Tactile Speed, Coordination Grooved Pegboard 5 
 Fine Motor Speed Finger Tapping 4 
 Grip Strength Dynamometer 3 
 Tremor 
 
Parallel Lines Test 
Tremometer 
Hand Steadiness Test 
3 
3 
5 
 Visual Reaction time Visual Attention test (VAT) 12 
 Somatosensory Luria Motor Items 1 
    
Sensory Vision Visual acuity (Snellen) 3 
 Vision Contrast sensitivity (Vistech 6000) 15 
 Vision Color Confusion Index (Lanthony D-
15) 
5 
 Vision Schirmer Strips 2 
    
Cognitive    
 Perceptual-motor speed Cancellation H or symbol 3 
 Perceptual-motor speed / visual 
memory 
Symbol Digit / Symbol Digit (recall) 3 
 Learning / Sustaining 
Concentration and Memory 
Auditory Trigrams (ACT) 10 
 Verbal – Reading level Wide Range Achievement Test-3, 
Reading Subtest 
10 
 Verbal Fluency COWAT 4 
 Category Fluency Animal Naming 2 
  Boston Naming Test  
 Auditory memory Digit Span (forward and backward) 5 
 Executive function D-KEFS Sorting Test 5 
WMSIII Spatial Memory Spatial Span (forward and backward) 5 
 Verbal Learning Word Lists I &II 10 
WAISIII  Block Design 8 
  Arithmetic 8 
  Picture Completion 8 
 Perceptual-motor speed / visual 
memory 
Digit Symbol Coding & Recall 5 
 Visual Memory Rey Osterreith, copy, recall & delay 10 
 Information Processing & 
Concept shifting 
Trails A and B 
Stroop Color Word Test 
5 
4 
 Malingering Rey 15 Item and/or 
Tomm Test of Malingering 
3 
10 
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APPENDIX C: Tests of Affect, Mood 
 
Test Duration (min)
Symptom Checklist 90 - R  15 
Relative Patient Questionnaire 10 
Profile of Mood States (POMS) 10 
Beck Depression & Beck Anxiety Scales 10 
Behavioral. Risk Factor Survey  BRFSS (days per month of good mental and 
physical health 
5 
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APPENDIX D:  
Differential diagnosis of Parkinsonism  
(Hobson, 2003, reproduced with permission) 
 
Primary neurodegenerative disorders with Parkinsonism: 
Inherited: 
Genetic Parkinson’s disease; [types with confirmed gene site and inheritance type] 
Alzheimer’s disease 
Huntington’s disease 
Spinocerebellar atrophies (SCA2, SCA3) 
Neuro-acanthocytosis 
Dopa responsive dystonia (DRD) 
Dentato Rubral Pallidal Luysian atrophy (DRPLA) 
Pantothenate kinase-associated neurodegeneration (PKAN) formerly Hallervorden Spatz 
syndrome  
Familial depression, alveolar hypoventilation and Parkinsonism 
Neuronal intranuclear inclusion disease 
Sporadic: 
Idiopathic Parkinson’s disease  
Parkinson ‘Plus’ syndromes: 
Progressive supranuclear palsy 
Multiple system atrophy 
Cortical basal ganglionic degeneration 
Dementia with Lewy bodies 
Alzheimer’s disease  
Pick’s disease 
ALS-Parkinson-dementia of Guam 
Hemiparkinsonism with hemiatrophy 
Secondary disorders with Parkinsonism: 
Inherited: 
Wilson’s disease 
Gauchers disease  
GM1 gangliosidosis  
Chediak-Higashi syndrome 
Sporadic: 
Toxic (1-methyl-4-phenyl-1,2-5,6-tetrahydropyridine (MPTP), carbon monoxide, carbon 
disulfide, cyanide, manganese)  
Hepatocerebral degeneration (non-Wilsonian) 
Endocrine (hypothyroidism, hypoparathyroidism) 
Mass lesions (arteriovenous malformation, neoplasm - primary or metastatic or paraneoplastic 
syndrome)  
Vascular (vasculitis, infarction, lacunar state) 
Infection related (viral encephalitis, syphilis, HIV, Creutzfeldt-Jakob disease) 
Trauma 
Autoimmune or inflammatory 
Lack of substrate (hypoxia, hypoglycemia) 
Others: 
Normal pressure hydrocephalus 
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Medication induced (direct or withdrawal) 
Classic neuroleptics (e.g. haloperidol, chlorpromazine, perphenazine)  
Novel neuroleptics  (e.g. risperidone tartrate, olanzapine) 
Dopamine reuptake blockers (e.g. reserpine, tetrabenazine)  
Gastrointestinal dopamine blockers  (e.g. metoclopramide) 
Calcium channel blockers (e.g. flunarizine hydrochloride, verapamil, amlodipine) 
Selective serotonin reuptake inhibitors (e.g. fluoxetine hydrochloride) 
Tricyclics (e.g. amytriptyline) 
Anticonvulsants (e.g. diphenylhydantoin, carbamazepine, valproic acid) 
Monoamine oxidase inhibitors (e.g. phenelzine) 
Benzodiazepines (e.g. diazepam, clonazepam, bromazepam) 
Other medications: Trazodone hydrochloride, buspirone, lithium, 
amphetamines, cocaine, meperidine, amiodarone, H1 
and H2 blockers. 
 
